Webinar: rAAV genome sequencing uncovers transgene integrity and packaging impurities
Recombinant adeno-associated viruses (rAAVs) are considered a promising delivery system for gene therapy medicines. This webinar highlighted how nanopore sequencing was evaluated as a comprehensive and sensitive QC method for rAAVs, supporting internal research activities at AstraZeneca.
During this webinar, viewers learnt:
Raw material validation through whole plasmid sequencing
ITR-ITR sequencing of whole AAV genomes and truncation hotspot detection
Contamination detection in bioreactor batches through sequencing of residual DNA
